Other Relevant Articles - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study
Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents
Clinical Implications of Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion: Role of Antegrade and Retrograde Crossing Techniques
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion The REVASC Trial
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI
Management of No-Reflow Phenomenon in the Catheterization Laboratory
Developing and Testing a Personalized, Evidence-Based, Shared Decision-Making Tool for Stent Selection in Percutaneous Coronary Intervention Using a Pre-Post Study Design

Guideline

2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL：J Am Coll Cardiol.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

5550

Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF